Abstract
Benzophenonehydrazone Schiff bases 1-25 were synthesized and their in vitro antiglycation potential has been studied. Out of twenty-five compounds, thirteen showed varying degrees of antiglycation activity with IC50 values ranging between 25.7 - 305 μM, if compared with the standard rutin (IC50 = 70.5 ± 0.50 μM). Compounds 21 (2,3- dihydroxybenzaldehyde N-(diphenylmethylene)hydrazine) IC50 = 25.7 ± 0.003 μM, 14 (diphenylmethanone N-[1-(2,4- dihydroxy-5-nitrophenyl)ethylidene]hydrazine) IC50 = 36.6 ± 0.004 μM, 6 (3,4-dihydroxybenzaldehyde N- (diphenylmethylene)hydrazine) IC50 = 49.5 ± 0.001 μM, 13 (diphenylmethanone N-[1-(2,5-dihydroxyphenyl)ethylidene] hydrazine) IC50 = 52.6 ± 0.023 μM, and 15 (diphenylmethanone N-[1-(3,4-dihydroxyphenyl)ethylidene]hydrazine) IC50 = 57 ± 0.002 μM, showed showed much better antiglycation potential superior to the standard rutin. The compounds 7 (2,5- dihydroxybenzaldehyde N-(diphenylmethylene)hydrazine) IC50 = 66 ± 0.002 μM, and 25 (diphenylmethanone N-[1-(2,5- dihydroxyphenyl)propylidene] hydrazine) IC50 = 67.9 ± 0.001 μM showed compareably good antiglycation activity to standard rutin. All compounds were characterized by spectroscopic techniques and gave satisfactory elemental analysis.
Keywords: Benzophenonehydrazone, Schiff bases, antiglycation, AGEPs
Medicinal Chemistry
Title:Synthesis of Benzophenonehydrazone Schiff Bases and their In Vitro Antiglycating Activities
Volume: 9 Issue: 4
Author(s): Khalid Mohammed Khan, Fazal Rahim, Nida Ambreen, Muhammad Taha, Momin Khan, Humaira Jahan, Najeebullah, Azizuddin Shaikh, Sarosh Iqbal, Shahnaz Perveen and Muhammad Iqbal Choudhary
Affiliation:
Keywords: Benzophenonehydrazone, Schiff bases, antiglycation, AGEPs
Abstract: Benzophenonehydrazone Schiff bases 1-25 were synthesized and their in vitro antiglycation potential has been studied. Out of twenty-five compounds, thirteen showed varying degrees of antiglycation activity with IC50 values ranging between 25.7 - 305 μM, if compared with the standard rutin (IC50 = 70.5 ± 0.50 μM). Compounds 21 (2,3- dihydroxybenzaldehyde N-(diphenylmethylene)hydrazine) IC50 = 25.7 ± 0.003 μM, 14 (diphenylmethanone N-[1-(2,4- dihydroxy-5-nitrophenyl)ethylidene]hydrazine) IC50 = 36.6 ± 0.004 μM, 6 (3,4-dihydroxybenzaldehyde N- (diphenylmethylene)hydrazine) IC50 = 49.5 ± 0.001 μM, 13 (diphenylmethanone N-[1-(2,5-dihydroxyphenyl)ethylidene] hydrazine) IC50 = 52.6 ± 0.023 μM, and 15 (diphenylmethanone N-[1-(3,4-dihydroxyphenyl)ethylidene]hydrazine) IC50 = 57 ± 0.002 μM, showed showed much better antiglycation potential superior to the standard rutin. The compounds 7 (2,5- dihydroxybenzaldehyde N-(diphenylmethylene)hydrazine) IC50 = 66 ± 0.002 μM, and 25 (diphenylmethanone N-[1-(2,5- dihydroxyphenyl)propylidene] hydrazine) IC50 = 67.9 ± 0.001 μM showed compareably good antiglycation activity to standard rutin. All compounds were characterized by spectroscopic techniques and gave satisfactory elemental analysis.
Export Options
About this article
Cite this article as:
Mohammed Khan Khalid, Rahim Fazal, Ambreen Nida, Taha Muhammad, Khan Momin, Jahan Humaira, Najeebullah , Shaikh Azizuddin, Iqbal Sarosh, Perveen Shahnaz and Iqbal Choudhary Muhammad, Synthesis of Benzophenonehydrazone Schiff Bases and their In Vitro Antiglycating Activities, Medicinal Chemistry 2013; 9 (4) . https://dx.doi.org/10.2174/1573406411309040013
DOI https://dx.doi.org/10.2174/1573406411309040013 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Clinical Applications of the CXCR4 Antagonist Bicyclam AMD3100
Mini-Reviews in Medicinal Chemistry Immunomodulation Via Targeted Inhibition of Antigen Receptor Signal Transduction
Cardiovascular & Hematological Disorders-Drug Targets Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Enzyme / Abzyme Prodrug Activation Systems: Potential Use in Clinical Oncology
Current Pharmaceutical Design Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
Current Medicinal Chemistry Novel Molecular-Targeted Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Harnessing the Tumor Suppressor Function of FOXO as an Alternative Therapeutic Approach in Cancer
Current Drug Targets Apoptosis and Acute Brain Ischemia in Ischemic Stroke
Current Vascular Pharmacology Molecular Remodeling of the Insulin Receptor Pathway by Thiazolidinediones in Type 2 Diabetes Mellitus: A Brief Review
Protein & Peptide Letters Papillary Thyroid Carcinoma in Pediatric Age: An Example of a Rare Tumour Managed Within a Cooperative Comprehensive Project
Current Pediatric Reviews Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals Recent Advances in Transcranial Focused Ultrasound (FUS) Triggered Brain Delivery
Current Drug Targets Effect of Curcumin on Pro-angiogenic Factors in the Xenograft Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Neurokinin Receptors as Potential Targets in Breast Cancer Treatment
Current Drug Discovery Technologies Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design Subject index to volume 3
Current Molecular Medicine Computational and Experimental Studies on Human Misshapen / NIK- Related Kinase MINK-1
Current Medicinal Chemistry Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Meet the Editorial Board:
Protein & Peptide Letters γ δ T Cells and Dendritic Cells: Close Partners and Biological Adjuvants for New Therapies
Current Molecular Medicine